Last reviewed · How we verify

conventional therapy plus MenSC transplantation

S-Evans Biosciences Co., Ltd. · Phase 1 active Biologic

conventional therapy plus MenSC transplantation is a Biologic drug developed by S-Evans Biosciences Co., Ltd.. It is currently in Phase 1 development. Also known as: Interferon, Bifendatatum, Ursodeoxycholic Acid, Menstrual blood-derived stem cells(MenSCs).

At a glance

Generic nameconventional therapy plus MenSC transplantation
Also known asInterferon, Bifendatatum, Ursodeoxycholic Acid, Menstrual blood-derived stem cells(MenSCs)
SponsorS-Evans Biosciences Co., Ltd.
ModalityBiologic
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about conventional therapy plus MenSC transplantation

What is conventional therapy plus MenSC transplantation?

conventional therapy plus MenSC transplantation is a Biologic drug developed by S-Evans Biosciences Co., Ltd..

Who makes conventional therapy plus MenSC transplantation?

conventional therapy plus MenSC transplantation is developed by S-Evans Biosciences Co., Ltd. (see full S-Evans Biosciences Co., Ltd. pipeline at /company/s-evans-biosciences-co-ltd).

Is conventional therapy plus MenSC transplantation also known as anything else?

conventional therapy plus MenSC transplantation is also known as Interferon, Bifendatatum, Ursodeoxycholic Acid, Menstrual blood-derived stem cells(MenSCs).

What development phase is conventional therapy plus MenSC transplantation in?

conventional therapy plus MenSC transplantation is in Phase 1.

Related